ALNY Stock News & Catalysts – Alnylam Pharmaceuticals

FEATURED

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

New

– AMVUTTRA Provided Sustained Benefit Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Over 60 Months, with a Consistent Safety Profile – – Benefit of Earlier TTR Silencing Compared to

Summary

Nov 9, 2026, 10:50 AM ·Business Wire

RECENT

Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership

Board authorizes share repurchase program reflecting confidence in Alnylam's long-term growth prospects and commitment to disciplined capital allocation Commercial leadership transition supports the Company's

Nov 4, 2026, 5:15 PM ·Business Wire

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November

Nov 4, 2026, 8:00 AM ·Business Wire

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

– Late-Breaking Presentation at AHA Will Feature Long-Term Results from the HELIOS-B Phase 3 Study, Including Two Years of Open-Label Extension Data in Patients with ATTR-CM – – HELIOS-B Post Hoc Analysis

Nov 3, 2026, 8:30 AM ·Business Wire

Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop

LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Investors who lost money on Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke

Oct 29, 2026, 5:40 PM ·Globe Newswire

Did You Lose Money on Alnylam Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. Smith Continues Securities Fraud Investigation After 28.31% Share Price Decline

BENSALEM, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Investors who suffered losses on Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") stock may have claims to recover those losses. The Law

Oct 29, 2026, 4:40 PM ·Globe Newswire

Lost Money on Alnylam Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Continues Investigating Potential Securities Fraud After 28.31% Stock Decline

LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R.

Oct 29, 2026, 3:40 PM ·Globe Newswire

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

− Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) – − Expands

Oct 29, 2026, 8:00 AM ·Business Wire

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

- Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64% at month 3 with individual reduction of up to 83% and encouraging safety and tolerability with potential for twice

Oct 23, 2026, 3:45 AM ·Business Wire

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026,

Oct 15, 2026, 8:00 AM ·Business Wire

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc.

Oct 5, 2026, 11:00 AM ·Globe Newswire

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:ALNY)

Oct 5, 2026, 9:00 AM ·Globe Newswire

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:ALNY) on behalf of

Oct 2, 2026, 5:40 PM ·Globe Newswire

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

– Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM Diagnosis – – ‘Play by Play’ Uses Sports to Highlight the

Sep 29, 2026, 9:00 AM ·Business Wire

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st

Sep 2, 2026, 8:00 AM ·Business Wire

Alnylam Pharmaceuticals, Inc. ALNY · News